Long-Term Follow-up Protocol for Subjects Treated With JCAR015
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs JCAR 015 (Primary)
- Indications Acute lymphoblastic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Juno Therapeutics
- 01 Mar 2017 According to a Juno Therapeutics media release, the company has made a strategic decision to cease development of JCAR015.
- 01 Mar 2017 According to a Juno Therapeutics media release, status changed from recruiting to discontinued.
- 18 Aug 2016 Status changed from not yet recruiting to recruiting.